從循證醫學角度看多巴胺受體激動劑在帕金森病治療中的作用_《中國循證醫學雜志》

作者：

 劉鳴 , 郝子龍

四川大學華西醫院神經內科（成都 610041）;

關鍵詞：

左旋多巴多巴胺受體激動劑帕金森病循證醫學

DOI：

10.7507/1672-2531.20100391

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

多巴胺受體激動劑在帕金森病治療中尤其是在早期治療中的地位成為近年帕金森病治療領域的熱點問題。多巴胺受體激動劑能作為起始首選用藥嗎？多巴胺受體激動劑能改善患者的自然病程嗎？多巴胺受體激動劑有神經保護作用嗎？在何時何種情況下可選用多巴胺受體激動劑？本文將從循證醫學的角度闡述多巴胺受體激動劑治療的利弊，為臨床決策提供依據。

引用本文： 劉鳴,郝子龍. 從循證醫學角度看多巴胺受體激動劑在帕金森病治療中的作用. 中國循證醫學雜志, 2010, 10(3): 232-234. doi: 10.7507/1672-2531.20100391 復制

1.	Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet, 2009, 373(9680): 2055-2066.
2.	中華醫學會神經病學分會帕金森病及運動障礙學組. 中國帕金森病治療指南(第二版). 中華神經科雜志, 2009, 42(5): 352-355.
3.	劉鳴, 謝鵬, 主編. 神經內科學. 北京: 人民衛生出版社, 2008.
4.	Stowe RL, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006564. DOI: 10.1002/14651858. CD006564.pub2.
5.	Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord, 2009, 15(4): 287-294.
6.	Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol, 2006, 13(11): 1170-1185.
7.	National Collaborating Centre for Chronic Conditions. Parkinson’s disease. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians, 2006. p. 237.
8.	Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71(7): 474-480.
9.	Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at.
10.	Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287(13): 1653-1661.
11.	Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 2003, 54(1): 93-101.
12.	Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2002, 58(1): 11-17.
13.	劉鳴, 臨床個體化處理應盡可能循證決策. 中國循證醫學雜志, 2007, 7(2): 83-84.
14.	years. Mov Disord, 2005, 20(2): 190-199.

1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet, 2009, 373(9680): 2055-2066.
2. 中華醫學會神經病學分會帕金森病及運動障礙學組. 中國帕金森病治療指南(第二版). 中華神經科雜志, 2009, 42(5): 352-355.
3. 劉鳴, 謝鵬, 主編. 神經內科學. 北京: 人民衛生出版社, 2008.
4. Stowe RL, Ives N, Clarke CE, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD006564. DOI: 10.1002/14651858. CD006564.pub2.
5. Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord, 2009, 15(4): 287-294.
6. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur J Neurol, 2006, 13(11): 1170-1185.
7. National Collaborating Centre for Chronic Conditions. Parkinson’s disease. National clinical guideline for diagnosis and management in primary and secondary care. London (UK): Royal College of Physicians, 2006. p. 237.
8. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology, 2008, 71(7): 474-480.
9. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at.
10. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287(13): 1653-1661.
11. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol, 2003, 54(1): 93-101.
12. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2002, 58(1): 11-17.
13. 劉鳴, 臨床個體化處理應盡可能循證決策. 中國循證醫學雜志, 2007, 7(2): 83-84.
14. years. Mov Disord, 2005, 20(2): 190-199.

《中國循證醫學雜志》

從循證醫學角度看多巴胺受體激動劑在帕金森病治療中的作用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

從循證醫學角度看多巴胺受體激動劑在帕金森病治療中的作用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料